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Insulin activates sterol regulatory element-binding protein-1c
(SREBP-1c) in liver, thereby increasing fatty acid and triglyceride syn-
thesis. We created a line of transgenic rats that produce epitope-
tagged human SREBP-1c in liver under control of the constitutive
apolipoprotein E promoter/enhancer. This systemallowsus todissect
the pathway by which insulin stimulates SREBP-1c processing with-
out interference by the insulin-mediated increase in SREBP-1cmRNA.
Rats are used because freshly isolated rat hepatocytes respondmuch
more robustly to insulin than domouse hepatocytes. The data reveal
that insulin-mediated stimulation of SREBP-1c processing requires
themechanistic target of rapamycin complex 1 (mTORC1), which also
is required for insulin-mediated SREBP-1cmRNA induction. However,
in contrast to mRNA induction, insulin stimulation of SREBP-1c pro-
cessing is blocked by an inhibitor of p70 S6-kinase. The data indicate
that the pathways for insulin enhancement of SREBP-1c mRNA and
proteolytic processingdiverge aftermTORC1. Stimulation of process-
ing requires the mTORC1 target p70 S6-kinase, whereas induction of
mRNA bypasses this enzyme. Insulin stimulation of both processes is
blocked by glucagon. The transgenic rat system will be useful in
further deﬁning the molecular mechanism for insulin stimulation of
lipid synthesis in liver in normal and diabetic states.
mTORC1 kinase | lipid metabolism
The liver plays a unique role in lipid metabolism because it isthe only organ that synthesizes fatty acids (FAs) and trigly-
cerides (TGs) for export to other tissues. These synthetic pro-
cesses are controlled reciprocally by insulin and glucagon, which
are secreted by the pancreas and delivered directly to the liver
via the portal vein. Precise control is important because excess
FA synthesis leads to elevated FAs in muscle, thereby contrib-
uting to the peripheral insulin resistance and lipotoxicity seen in
type 2 diabetes. Excess FA synthesis also causes fatty liver, which
sometimes leads to cirrhosis and liver failure (1, 2).
Insulin stimulates FA synthesis in liver by increasing the mRNA
and the processed nuclear form of sterol regulatory element-
binding protein-1c (SREBP-1c), a transcription factor that acti-
vates all the genes needed to produce FAs and TGs in liver (3). Of
the three SREBP isoforms, SREBP-1c is the one whose expression
is highest in liver, and it is the only one that is controlled primarily
by insulin. For this reason, deﬁnitive studies of insulin-mediated
activation of SREBP-1c must be performed with liver cells.
Studies of insulin action on liver cells are difﬁcult because none
of the established hepatocyte cell lines responds to insulin with the
robustness observed in the livers of living animals. Moreover, freshly
isolated hepatocytes lose their insulin responsiveness within 48–72 h
after isolation. Therefore, studies must be performed in living ani-
mals or with freshly isolated hepatocytes that are less than 72 h old.
Even more perplexing are species differences. Although mouse and
rat livers manifest robust elevations in SREBP-1c mRNA when
exposed to insulin in vivo, freshly isolated mouse hepatocytes show
much less sensitivity to insulin than rat hepatocytes. Although
numerous studies have dealt with the regulation of SREBP mRNA
and processing in various tissues (reviewed in ref. 4), only a few have
been carried out in freshly isolated rat hepatocytes (5–11).
SREBP-1c, like the other two SREBP isoforms, is synthesized as
a membrane-bound protein embedded in endoplasmic reticulum
(ER) membranes (12). Immediately after synthesis, SREBP forms
a complex with Scap, a polytopic membrane protein that facilitates
incorporation of the SREBP into COPII-coated vesicles that bud
from the ER and fuse with the Golgi apparatus (13). There
SREBP is processed by two proteases to liberate a soluble frag-
ment that travels to the nucleus and activates transcription.
Movement of the Scap/SREBP complex is inhibited by Insig pro-
teins, intrinsic ER proteins that bind the Scap/SREBP complex
and prevent its movement to the Golgi (13). The liver produces
two Insig isoforms, Insig-1 and Insig-2, both of which retard the
movement of Scap/SREBP complexes (14).
Insulin activates SREBP-1c in liver at two levels. It increases
SREBP-1c processing to liberate the nuclear form, and it increases
transcription of the SREBP-1c gene, leading to increased SREBP-
1c mRNA and precursor protein (12, 15). Under optimal con-
ditions with freshly isolated rat hepatocytes in cell culture, insulin
can induce the SREBP-1c mRNA by as much as 40-fold within 6 h
(8, 11). This increase is blocked by wortmannin, an inhibitor of
phosphatidylinositol 3-kinase, an early enzyme in the insulin-sig-
naling cascade. The increase also is blocked by low concentrations
of rapamycin, indicating that the mechanistic target of rapamycin
complex 1 (mTORC1) is required also. Importantly, the increase
was not blocked by an inhibitor of p70 S6-kinase (S6K), one of the
major downstream targets of mTORC1, suggesting that another
target of mTOR is involved (11). Remarkably, rapamycin did not
block the other major metabolic effect of insulin in liver, namely,
the reduction in mRNAs encoding enzymes of gluconeogenesis.
This ﬁnding indicated that the insulin-signaling pathway diverges
upstream ofmTORC1, with one pathway leading throughmTORC1
to increase SREBP-1c mRNA and the other bypassing mTORC1
and downregulating the gluconeogenic mRNAs (11).
The other action of insulin on SREBP-1c, the increase in pro-
teolytic processing, has been difﬁcult to study because the increase
in SREBP-1c mRNA and precursor protein levels makes an in-
crease in nuclear SREBP-1c difﬁcult to interpret. Hegarty et al. (9)
attempted to circumvent this problem by ﬁrst treating freshly iso-
lated rat hepatocytes with an activator of liver X receptor (LXR),
which increased SREBP-1c mRNA without stimulating proteolytic
processing, and then adding insulin to stimulate processing. They
found that the insulin stimulation of processing was blocked by
wortmannin. However, further advances with this approach may be
limited because of the requirement for an LXR activator, which
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might contribute to insulin’s action in stimulating SREBP-1c pro-
cessing (8).
In the current study, we have taken an alternative approach. To
eliminate transcriptional effects of insulin on the SREBP-1c gene,
we generated a line of transgenic rats that produce epitope-tag-
ged SREBP-1c driven by a human apoE promoter/enhancer ex-
pression cassette, which is not regulated by insulin. Because rat
hepatocytes give a dramatically more robust response to insulin
than do mouse hepatocytes (6, 7), we injected our transgene into
fertilized eggs of rats instead of mice. When treated with insulin,
freshly isolated hepatocytes from these transgenic rats exhibited
a consistent increase in the amount of the transgene-encoded
nuclear SREBP-1c, allowing further dissection of the responsible
signaling mechanism.
Results
Fig. 1A shows the HA-tagged human SREBP-1c transgene that
was used to generate the transgenic rats. Expression was medi-
ated by the apoE promoter and its hepatic control region, which
maximizes expression in hepatocytes. The transgenic rat line,
hereafter designated “TgHA-hSREBP-1c,” was maintained as
hemizygotes by breeding with WT Sprague–Dawley rats. In the
liver, the amount of human SREBP-1c mRNA from the trans-
gene was ∼2.5 times that of the endogenous rat SREBP-1c
mRNA when the ad libitum-fed animals were killed 6 h into the
dark cycle (Fig. 1B). Lower levels of transgene expression were
seen in brain, spleen, and lung.
In WT rats, as observed previously (11), the amount of
SREBP-1c mRNA declined dramatically after a 48-h fast and
increased markedly after the animals had been re-fed with a high-
carbohydrate diet for 6 h (Fig. 2A, Left). Nearly identical changes
were observed when the endogenous SREBP-1c mRNA was
measured in the transgenic rats. In marked contrast, the transgene
mRNA did not decline signiﬁcantly when the animals were fasted,
nor did it rise when they were re-fed (Fig. 2A, Right). SREBP-1c
protein levels were measured by immunoblots (Fig. 2B). The
precursor and nuclear forms of endogenous SREBP-1c declined
dramatically during fasting and were restored by refeeding in
transgenic rats as well as in WT animals (lanes 1–6). Immunoblots
of the SREBP-1c precursor generated by the transgene revealed
little decrease on fasting (lanes 4–6). Nevertheless, the nuclear
form was reduced dramatically, suggesting a decrease in pro-
teolytic processing. Refeeding produced an increase in the nuclear
form, again without a change in the precursor, suggesting that pro-
teolytic processing was activated.
To determine whether insulin mediates the increase in SREBP-
1c processing, we used fresh hepatocytes from the transgenic rats
(Fig. 3). When the cells were exposed to 100 nM insulin, the
increase in nuclear SREBP-1c was maximal within 15 min, and
the nuclear protein remained elevated through 6 h (Fig. 3A).
Similar results were obtained with insulin concentrations as low as
10 nM. The addition of glucagon decreased the amount of basal
and insulin-induced nuclear SREBP-1c, as determined by densi-
tometric staining of immunoblots (Fig. 3B). In the presence of
3 nM glucagon, basal nuclear SREBP-1c was reduced by 80%,
and the absolute amount of insulin stimulation was reduced by
70%. Glucagon did not signiﬁcantly reduce the amount of the
precursor encoded by the SREBP-1c transgene.
Nuclear SREBPs are known to be degraded rapidly by pro-
teasomal proteolysis (16). The rapidity of the insulin effect (Fig.
3A) suggests that insulin acts by increasing the production of the
nuclear form rather than by blocking its degradation. To test this
conclusion in another way, we made use of the proteasome in-
hibitor MG132 (Fig. 3 C and D). In the absence of MG132, the
addition of insulin to the transgenic hepatocytes produced a six-
fold increase in nuclear SREBP-1c as determined by densito-
metric scans. Addition of MG132 also caused an increase in
nuclear SREBP-1c, presumably by preventing degradation.
However, the amount of the nuclear protein rose further when
insulin was added, even when the nuclear protein was stabilized
by MG132, indicating that insulin acts by increasing production
of the nuclear form rather than by blocking degradation.
To dissect the insulin-signaling pathway that mediates the in-
crease in SREBP-1c processing in transgenic hepatocytes, we
used the three inhibitors shown in Fig. 4. In the absence of
inhibitors, insulin increased the amount of nuclear SREBP-1c
(lane 2). As expected, this increase was blocked by wortmannin
(lane 3). It also was blocked by rapamycin (lane 4). The increase
in SREBP-1c processing was inhibited by LYS6K2, an inhibitor
of S6K that blocked the phosphorylation of S6 (lane 5). The
result with LYS6K2 was unexpected, because we reported pre-
viously that LYS6K2 did not block the insulin-induced increase
of SREBP-1c mRNA (11). As a control, neither rapamycin nor
LYS6K2 blocked the insulin-induced phosphorylation of Akt.
Fig. S1 shows a compilation of results from 10 independent
experiments with rapamycin and eight experiments with
LYS6K2, all of which found that both inhibitors blocked the
insulin-induced processing of transgene-encoded SREBP-1c. To
conﬁrm the failure of LYS6K2 to block the mRNA induction of
SREBP-1c, we used the conditions of Li et al. (11). Hepatocytes
from the transgenic rats were pretreated for 30 min with vehicle,
rapamycin, or LYS6K2. The cells then were incubated for 6 h in
the absence or presence of 30 nM insulin. Cells were harvested,
and the amount of endogenous SREBP-1c mRNA was quanti-
ﬁed by real-time PCR. Nuclear extracts were prepared from
identically treated cells and used for the measurement of nuclear
SREBP-1c derived from the transgene as determined by SDS/
PAGE, immunoblotting, and densitometric scanning (Fig. S2).
After 6 h, insulin increased the amount of endogenous SREBP-
1c mRNA by 14-fold. Rapamycin reduced this increase by 85%,
but LYS6K2 had no effect. In similarly treated cells, insulin
Fig. 1. Generation of transgenic rats expressing HA-tagged full-length hu-
man SREBP-1c in liver. (A) The transgene construct contains a cDNA fragment
encoding HA-tagged full-length human SREBP-1c (amino acids 2–1122) under
control of human apoE promoter and its hepatic control region. (B) Tissue
distribution of human HA-hSREBP-1c transgene. Male TgHA-hSREBP-1c rats
(2–3 mo old) that were fed a chow diet ad libitum were killed 6 h into the
dark cycle. Equal amounts of total RNA from the indicated tissues of four
transgenic rats were pooled and subjected to real-time PCR. Each value rep-
resents the amount of transgenic human SREBP-1c mRNA in the indicated
tissue relative to that of endogenous rat SREBP-1c mRNA in the liver, which is
arbitrarily deﬁned as 1. The cycle threshold (Ct) values for endogenous and
transgenic SREBP-1c in the liver were 24.4 and 23.0, respectively.
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increased transgene-encoded nuclear SREBP-1c by 12-fold over
the course of 6 h. Rapamycin blocked this increase by 64%, and
LYS6K2 reduced it by 74%. Thus, the LYS6K2 inhibition was
speciﬁc for protein processing and not for mRNA induction.
To provide further evidence that rapamycin and LYS6K2
block processing by inhibiting their respective enzymes, we per-
formed dose–response curves with the inhibitors and measured
phospho-S6 and nuclear SREBP-1c in the same cells (Fig. 5).
Within the range of precision of these immunoblotting assays,
the degree of inhibition of SREBP-1c processing by rapamycin
and LYS6K2 was well correlated with the degree of reduction of
phospho-S6, supporting the notion that the two inhibitors work
by blocking the activity of S6K (Fig. 5 C and D). Again, insulin-
induced phosphorylation of Akt was not blocked by either of
the inhibitors.
Fig. 6 shows an in vivo experiment designed to determine
whether rapamycin blocks the increase in SREBP-1c processing in
livers of rats after refeeding. Transgenic rats were fasted for 48 h
and then re-fed for 3 h. One hour before refeeding, they were
injected i.p. with vehicle or with rapamycin. Refeeding increased
the amount of nuclear SREBP-1c derived from the transgene as
well as the endogenous gene (Fig. 6A). Both of these feeding-
induced increases were decreased by rapamycin. As previously
reported (11), rapamycin also prevented the refeeding-induced
increase in endogenous SREBP-1c mRNA (Fig. 6B). As a positive
control, rapamycin prevented the increase in phospho-S6 that was
induced by refeeding (Fig. 6A). After refeeding, plasma insulin
rose equally in the vehicle- and rapamycin-treated rats (Fig. 6C),
indicating that the rapamycin-mediated inhibition of SREBP-1c
processing and transcription was not the result of decreased in-
sulin availability.
Discussion
The pathways for insulin signaling in liver are complex. mTORC1
plays a central role, but it is embedded in an intricate web of feed-
forward loops, feedback loops, bypass loops, and negative regu-
lators of negative regulators whose interactions render deﬁnitive
study difﬁcult [for an illustration of this complexity, see ﬁgure 2 in
Laplante and Sabatini (17)]. Moreover, insulin-signaling pathways
differ in different cell types, and they are affected by the actions
of other hormones. For this reason, our laboratory (6, 8, 11) and
others (5, 9, 10) have focused on rat hepatocytes, which show ro-
bust responses to insulin both in living animals and immediately
after their isolation from cell culture. Here we introduce a system
for studying insulin stimulation of SREBP-1c processing, namely,
a transgenic rat expressing human SREBP-1c mRNA in liver via
a promoter/enhancer that is not regulated by insulin.
Earlier studies of mRNA expression in rat hepatocytes
revealed a bifurcation in the insulin pathway in liver (11). One
branch leads through mTORC1 and activates lipid synthesis
through an increase in SREBP-1c; the other branch bypasses
mTORC1 and leads to a reduction in gluconeogenesis mediated
by a reduction in the activity of Foxo1 (18). Here we show that
the branch leading to increased SREBP-1c itself bifurcates distal
to mTORC1. This latter bifurcation is illustrated in Fig. 7. One
pathway leads to an increase in SREBP-1c mRNA and SREBP-
1c precursor protein. This action is not inhibited by the S6K
Fig. 2. Effect of fasting and refeeding on the hepatic levels of endogenous
and transgenic SREBP-1c mRNAs and proteins in WT and TgHA-hSREBP-1c
rats. Male WT and transgenic TgHA-hSREBP-1c (Tg) littermates (2–3 mo old,
four rats per group) were subjected to fasting and refeeding as described in
Materials and Methods. The nonfasted group (N) was fed a chow diet ad
libitum, the fasted group (F) was fasted for 48 h, and the re-fed group (R)
was fasted for 48 h and re-fed a high-carbohydrate diet for 6 h before study.
(A) Equal amounts of total RNA from livers of four rats were pooled and
subjected to real-time PCR. For the endogenous rat SREBP-1c mRNA, each
value represents the amount relative to the amount in the nonfasted WT
rats, which was arbitrarily deﬁned as 1 (Ct value, 24.2). For the transgenic
human SREBP-1c mRNA, the level in the nonfasted transgenic rats was ar-
bitrarily deﬁned as 1 (Ct value, 23.2). (B) Liver membrane and nuclear extract
fractions were prepared individually and pooled from four rats per group.
The mean values for the total amount of protein in the 24 membrane and
nuclear extract fractions were 2,459 and 458 μg, respectively. Aliquots of
membrane (30 μg) and nuclear extract (30 μg) fractions were subjected to
8% SDS/PAGE and immunoblot analysis with both anti-rat SREBP-1 and anti-
HA antibodies to detect membrane-bound precursor (P) and cleaved nuclear
(N) forms of endogenous rat SREBP-1 and HA-tagged transgenic human
SREBP-1c, respectively. The exposure times for the autoradiograms were 1 s
for all precursors, 10 s for transgenic nuclear extract, and 60 s for endoge-
nous nuclear extracts.
Fig. 3. Insulin-mediated stimulation of proteolytic processing of transgenic
SREBP-1c in primary rat hepatocytes. Hepatocytes from nonfasted TgHA-
hSREBP-1c rats were prepared and plated on day 0 as described in Materials
and Methods. (A) Time course of insulin effect. On day 1, the cells were left
untreated or treated with 100 nM insulin for the indicated time, harvested,
and then pooled (three dishes of cells per sample) for immunoblot analysis of
precursor (P) and nuclear (N) forms of transgenic HA-hSREBP-1c protein. The
gels were exposed to ﬁlm for 5 s. (B) Effect of glucagon. On day 1, cells were
left untreated or were pretreated for 2 h with the indicated concentration of
glucagon, after which the cells were left untreated or were treated with 30
nM insulin for 1 h before harvest as above. Immunoblot analysis of nuclear
transgenic HA-hSREBP-1c was carried out and then was scanned and quanti-
ﬁed by densitometry as described in SI Materials andMethods. The amount of
the cleaved nuclear HA-hSREBP-1c protein in the cells without any treatment
was arbitrarily set at 1. (C andD) Effect of proteasomal inhibitor. (C) On day 1,
hepatocytes were left untreated or were treated 10 nM insulin for 1 h in the
absence or presence of 10 μM MG132 (proteasomal inhibitor) and then were
harvested for immunoblot analysis as inA. The gels were exposed toﬁlm for 5–
10 s. (D) The gel of nuclear extract fractions (N) in C was scanned and
quantiﬁed by densitometry as in B, with the amount of nuclear HA-hSREBP-
1c protein in cells without any treatment arbitrarily set at 1.
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inhibitor and therefore is independent of S6K. The other path-
way leads to an increase in the proteolytic processing of the
SREBP-1c precursor protein. This pathway is inhibited in par-
allel with the decline in phospho-S6 when S6K is blocked by
LYS6K2 (Figs. 4 and 5). Both the SREBP-1c mRNA induction
and the increase in SREBP-1c processing are blocked by low
concentrations of rapamycin, indicating that mTORC1 is es-
sential for both processes. Both pathways also are blocked by
glucagon, acting through cAMP (Fig. 3B) (7, 15).
Although mTORC1 is essential for SREBP-1c activation in
liver, it is not sufﬁcient. This ﬁnding was reported initially by
Yecies et al. (19), who found that SREBP-1c mRNA is not ele-
vated in livers of mice with genetic ablation of TSC1, a negative
regulator of mTORC1, even though these animals have markedly
increased mTORC1 activity. Thus, insulin must regulate another
process in addition to activation of mTORC1, and activation of
both processes is required for induction of SREBP-1c mRNA.
The advantage of the current transgenic rat model is illus-
trated by the data in Fig. 2B. When WT rats were fasted, their
SREBP-1c mRNA declined dramatically, and as a result the
SREBP-1c precursor protein was not detectable. When the
animals were re-fed, the SREBP-1c mRNA increased, and so did
the precursor and nuclear forms of the protein (Fig. 2). From
such an experiment, it is impossible to tell whether insulin
increases SREBP-1c processing or whether it acts only to in-
crease the amount of the SREBP-1c precursor, whereupon
processing takes place through some constitutive mechanism. A
similar problem was encountered by Bae et al. (20), who dem-
onstrated clearly that knockdown of S6K by RNA interference in
mouse liver reduced nuclear SREBP-1c after refeeding, but they
could not distinguish an effect on processing versus an effect
on mRNA induction. When encoded in rats by the transgene,
SREBP-1c mRNA was present even in fasted animals, as was the
precursor protein. However, there was very little nuclear form,
indicating that processing was blocked. Refeeding increased the
nuclear form without increasing the amount of precursor, in-
dicating that the processing of SREBP-1c was enhanced (Fig. 2).
Although the SREBP-1c produced by the transgene provides
a good model for studying proteolytic processing, it is not a
model for SREBP-1c transcriptional activity. Insertion of an
epitope tag at the N terminus of an SREBP markedly reduces its
transcriptional activity. Indeed, in our transgenic rats, the amount
of SREBP-1c target mRNAs, including acetyl CoA carboxylase
and fatty acid synthase, was not elevated despite the 2.5-fold in-
crease in SREBP-1c mRNA.
Because nuclear SREBPs are known to be degraded rapidly by
proteasomes, we considered the possibility that insulin stabilized
Fig. 4. Effects of protein kinase inhibitors on insulin-stimulated proteolytic
processing of transgenic SREBP-1c in rat hepatocytes. Hepatocytes from
nonfasted TgHA-hSREBP-1c rats were prepared and plated on day 0. On day
1, cells were left untreated or were pretreated for 3 h with the indicated
protein kinase inhibitor: 0.2 μM wortmannin (lane 3), 0.1 μM rapamycin
(lane 4), or 3 μM LYS6K2 (lane 5). After this preincubation, the cells were left
untreated or were treated with 10 nM insulin for 30 min, harvested, and
then pooled (three dishes of cells per sample). Each sample was subjected to
immunoblot analyses of the following proteins: precursor (P) and nuclear (N)
forms of transgenic HA-hSREBP-1c, phosphorylated Akt (P-Akt), total Akt,
phosphorylated ribosomal protein S6 (P-S6), and total S6. Gels were exposed
to ﬁlm for 3–25 s.
Fig. 5. mTORC1 and S6K are required for insulin to stimulate proteolytic
processing of transgenic SREBP-1c in rat hepatocytes. Hepatocytes from
nonfasted TgHA-hSREBP-1c rats were prepared and plated on day 0. On day
1, cells were left untreated or were pretreated for 2 h with the indicated
concentration of rapamycin or LYS6K2, after which the cells were left un-
treated or were treated with 30 nM insulin for 1 h, harvested, and then
pooled (three dishes of cells per sample) for immunoblot analysis. (A and B)
Samples were subjected to immunoblot analysis as in Fig. 4. (C and D)
Quantiﬁcation of immunoblots. The gels of nuclear extract fractions (N) of
transgenic HA-hSREBP-1c protein and cytosol fractions of phosphorylated
ribosomal protein S6 (P-S6) in A and B were scanned and quantiﬁed by
densitometry. The amount of nuclear HA-hSREBP-1c or cytosol P-S6 protein
in cells treated with insulin alone (lanes 2 and 9) was arbitrarily set at 1.
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the nuclear form rather than increasing its production. Two
observations argued against this possibility. First, insulin in-
creased the steady-state level of nuclear SREBP-1c by four- to
ﬁvefold within 15 min (Fig. 3A), a rate that is much too fast to be
attributed to stabilization. Second, insulin increased the amount
of nuclear SREBP-1c even when degradation was blocked by
a proteasome inhibitor (Fig. 3C).
In addition to causing a spike in plasma insulin, refeeding also
causes a decline in glucagon (21). We showed earlier that glu-
cagon blocks the insulin induction of SREBP-1c mRNA in rat
hepatocytes (7). Here we show that glucagon also reduces the
insulin-mediated increase of SREBP-1c processing in transgenic
hepatocytes (Fig. 3B). Thus, in re-fed WT animals the dramatic
increase in nuclear SREBP-1c represents the combined effects of
insulin increase and glucagon reduction.
The transgenic rat model offers the promise of a system that
should allow more careful dissection of the mechanism by which
insulin activates SREBP-1c processing. In particular, it will be
necessary to deﬁne the presumptive target of S6K that leads to
the liberation of the Scap/SREBP-1c complex from the ER.
Materials and Methods
Materials. We obtained powdered bovine insulin from Sigma (catalog no.
I6634) and protein kinase inhibitors from sources as previously described (11).
LYS6K2, obtained from Eli Lilly and Company, is a highly selective ATP in-
hibitor of P70 S6K, having been tested against 83 other kinases and 45 cell-
surface receptors. A stock solution of 0.1 mM insulin was prepared by
dissolving the powder in 1% (vol/vol) acetic acid, after which the solution
was stored in multiple aliquots at −80 °C. All kinase inhibitors were prepared
in dimethyl sulfoxide and stored at −20 °C. Culture media, FCS, and collagen-
coated dishes were obtained from sources as described (11).
Generation of Transgenic Rats. To generate transgenic rats expressing full-
length human SREBP-1c in the liver, we used a pLiv-11 vector that contains the
constitutive human apoE promoter/enhancer and its hepatic control region
(22). The transgenic plasmid (pLiv-11-HA-hSREBP-1c) was generated by clon-
ing a cDNA fragment encoding the ORF of human SREBP-1c with an N-ter-
minal 3xHA tag into Mlu1-Cla1 sites of pLiv-11. The 11-kb SalI-SpeI fragment
of pLiv-11-HA-hSREBP-1c then was isolated and injected into the pronucleus
of Sprague–Dawley rat eggs as described (23). Transgenic founders were
identiﬁed by dot blot analysis and mated with WT Sprague–Dawley rats. To
genotype transgenic rats, ear-punch DNA was prepared with a direct lysis kit
(Viagen Biotech Inc.) and used for PCR with the primers 5′-GTGCTGGGAT-
TAGGCTGTTGCAGATAATGC-3′ and 5′-GGTACATCTTCAATGGAGTGGGTGCA-
GGCT-3′. Ear-punch DNA of transgenic rats produced a PCR product of 527
bp. The transgenic rats, hereafter designated TgHA-hSREBP-1c, were main-
tained as hemizygotes by breeding with WT Sprague–Dawley rats. Two in-
dependent lines were established, both exhibiting a two- to threefold over-
expression of hepatic HA-hSREBP-1c mRNA relative to the endogenous
SREBP-1c mRNA. All rats were housed in colony cages with a 12-h light/12-h
dark cycle and were fed Teklad Rodent Diet 2016 (Harlan Teklad). Before
blood and liver were obtained, rats were anesthetized in a bell-jar atmo-
sphere containing isoﬂurane. All animal experiments were performed with
the approval of the Institutional Animal Care and Use Committee at Uni-
versity of Texas Southwestern Medical Center.
Fasting and Refeeding Studies. The rats were divided into three groups:
nonfasted, fasted, and re-fed. The nonfasted group was fed a chow diet ad
libitum. The fasted group was fasted for 48 h, and the re-fed group was
fasted for 48 h and then re-fed a high-carbohydrate, fat-free diet (960238;
MP Biomedicals) for 3 or 6 h before study. Feeding regimens were carried
out in a staggered fashion so that all rats were euthanized at the same time.
In one experiment (Fig. 6), rats were injected i.p. with either vehicle alone
[14% ethanol, 5% (vol/vol) Tween 80, and 5% (vol/vol) polyethylene glycol
400] or vehicle containing 20 mg/kg rapamycin. Plasma insulin levels were
measured with a commercial ELISA kit (Crystal Chem). The plasma was
obtained from blood drawn from the inferior vena cava, which was col-
lected on ice in EDTA-coated tubes, separated by centrifugation, and
stored at −20 °C.
Primary Rat Hepatocytes. Primary hepatocytes were isolated from nonfasted
rats (male, 2–3 mo old) and cultured as previously described (11) with the
following minor modiﬁcations. On day 0, isolated hepatocytes were plated
onto collagen I-coated dishes (1 × 107 cells per 10-cm dish) in 10 mL medium
A [Medium 199 (Life Technologies) supplemented with 5% (vol/vol) FCS, 100
nM dexamethasone, 100 units/mL penicillin, and 100 μg/mL streptomycin
sulfate]. After incubation for 3–4 h at 37 °C in 5% CO2, the attached cells
were washed once with PBS and then incubated at 37 °C overnight in me-
dium B (medium A without FCS). Unless noted otherwise, on day 1 cells were
pretreated for 2 h with a direct addition of 10 μL dimethyl sulfoxide with or
without the indicated protein kinase inhibitor, after which the cells were
treated with a direct addition of 10 μL acidiﬁed water with or without
Fig. 6. Effect of mTORC1 inhibition on SREBP-1c processing (A) and SREBP-
1c transcription (B) in livers of TgHA-hSREBP-1c rats subjected to fasting and
refeeding. Male transgenic rats (2–3 mo old, four rats per group) were fasted
for 48 h or were fasted for 48 h and then re-fed a high-carbohydrate diet for
3 h before study. Animals in the re-fed group were injected i.p. with vehicle
or 20 mg/kg rapamycin (+Rap) 1 h before refeeding. (A) Liver membrane,
nuclear extract, and cytosol fractions were prepared individually and pooled
(four rats per group). Membrane and nuclear extract fractions were sub-
jected to immunoblot analysis to detect precursor (P) and nuclear (N) forms
of HA-tagged transgenic human SREBP-1c and endogenous rat SREBP-1 as in
Fig. 2. Immunoblot analysis of cytosolic phosphorylated ribosomal protein S6
(P-S6) and total S6 was carried out as described in SI Materials and Methods.
Gels were exposed to ﬁlm for 3–60 s. (B) Total liver RNA was prepared
individually and subjected to real-time PCR. Each bar (mean ± SEM of data
from four rats) represents the amount of endogenous SREBP-1c mRNA
relative to that in the fasted group, which was arbitrarily deﬁned as 1. (C)
Plasma insulin levels. Insulin was measured in plasma obtained immediately
after administration of anesthesia as described in Materials and Methods.
Each bar represents mean ± SEM of data from four rats.
Fig. 7. Pathways for insulin stimulation of SREBP-1c mRNA and proteolytic
processing diverge after mTORC1. Both processes are inhibited by glucagon
acting through cAMP.
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insulin. After incubation for the indicated time at 37 °C in 5% CO2, the cells
were harvested for immunoblot and RNA analysis.
Other Methods. Additional information about materials and methods is
provided in SI Materials and Methods.
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